Gene therapy using synthetic microRNA directed against GAD67 has beneficial effect on motor behaviour in 6-OHDA lesioned rats

Erika Elgstrand Wettergren, Luis Quintino and Cecilia Lundberg*

Abstract

**Background:** Modification of the glutamic acid decarboxylase (GAD) level is a promising future treatment tool for Parkinson's disease (PD). GAD is the rate-limiting enzyme in the synthesis of the inhibitory neurotransmitter gamma amino butyric acid (GABA) and modification of the GAD level could therefore potentially be used to alter the GABA output from a nucleus.

**Methods:** We have previously developed a synthetic microRNA (smiRNA1550) designed to knockdown the GAD isoform GAD67 and shown that it can efficiently knockdown the target protein. In this study we have further evaluated the therapeutic potential of smiRNA1550 in treating motor symptoms using the 6-OHDA rat model of PD and lentiviral vectors. The smiRNA was evaluated in striatum and substantia nigra pars reticulata (SNpr), two nuclei with increased GAD levels and GABA output in PD. The result was evaluated by behaviour tests and western blot. Differences between groups were assessed using analysis of variance (ANOVA) followed by the Tukey’s multiple comparison test for group comparisons.

**Results:** There was a beneficial effect in apomorphine-induced rotations after injection of LV-smiRNA1550 into SNpr.

**Conclusion:** These findings suggest that manipulation of the GABA system could be a valid approach for development of novel gene therapies for PD that warrant further study.

**Keywords:** Glutamic acid decarboxylase, synthetic microRNA, striatum, substantia nigra pars reticulata, parkinson’s disease, rat

Introduction

Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme in the production of the inhibitory neurotransmitter gamma amino butyric acid (GABA). Aberrant GAD expression and GABAergic signalling is involved in several diseases, such as Parkinson's disease (PD) [1,2]. In PD loss of dopamine causes an imbalance in the signalling pathways throughout the basal ganglia and ultimately difficulties in initiating movements. Normalisation of the GABA signalling could potentially alleviate some of these symptoms and this could be achieved by modifying the level of GAD.

Modification of the GAD level by gene therapy has been shown to be a promising future treatment option for PD. The studies performed so far have used adeno-associated vectors expressing GAD. Beneficial effects have been reported after injection into the subthalamic nucleus (STN), a glutamatergic nucleus that is over-active in PD, in rats with experimental PD, macaques with experimental PD and parkinsonian patients [3-8]. Modification of GAD in other nuclei may however also be beneficial.

Increased expression of GAD has previously been reported in striatum and substantia nigra pars reticulata (SNpr) following dopamine depletion [9,10] and modification of GAD in these nuclei may have beneficial effect on parkinsonian symptoms. This could be achieved by using RNA interference (RNAi). Studies have shown that highly efficient RNAi can be achieved by embedding a small interfering RNA (siRNA), complementary to a target mRNA, into a mir30 scaffold [11]. These synthetic microRNA (smiRNA) have several advantages over frequently used short-hairpin RNA (shRNA), both in terms of safety [12,13]
and in terms of versatility in the vector design [11,14].

We have recently constructed a smiRNA; smiRNA1550, directed against GAD67 [9]. GAD67 is one of two GAD isoforms found in the CNS [15]. We found that smiRNA1550 was able to efficiently knockdown the GAD67 protein levels in vitro to 20% of untreated cells. Moreover, smiRNA1550 was also able to normalise the GAD67 protein level in striatum of 6-OHDA lesioned rats without any signs of toxicity. These results show that smiRNA1550 is safe and that it is possible to knockdown endogenous GAD67 levels both in vitro and in vivo. However, it is still unclear if knockdown of GAD67 using smiRNA has any beneficial effect on PD symptoms. In this study we have evaluated possible beneficial effects of GAD67 down-regulation on motor behaviour in the 6-OHDA rat model of PD. We report a beneficial effect after injection of lentiviral vectors (LV) expressing smiRNA1550 into the SNpr, but not after injection into the striatum.

Material and methods

Production of lentiviral vectors

The LV-CMV-smiRNA1550 [9], LV-CMV-GFP [16] and LV-EF1α-GFP [16] vectors have been published elsewhere. The LV-EF1α-smiRNAαGFP and LV-EF1α-smiRNA1550 vectors were constructed using Gateway cloning (Invitrogen, Carlsbad, CA). Briefly, the dsRed-smiRNAαGFP fragment was amplified from a LV-CMV-smiRNAαGFP vector [17] and cloned into a pDONR221 vector, according to the manufacturers protocol, creating a pDONR221-smiRNAαGFP vector. A pDONR-smiRNA1550 vector was created by annealing the oligonucleotides coding for smiRNA1550 [9], cutting out smiRNAαGFP from pDONR-smiRNAαGFP using SpeI/XmaI (New England Biolabs, Ipswich, MA) and ligating the annealed oligonucleotides into the SpeI/Xmal site. The resulting vectors were combined with a pDONRP4P1R-EF1α and a pHg backbone to create the expression vectors LV-EF1α-smiRNAαGFP and LV-EF1α-smiRNA1550. Schematic maps of the vectors are shown in Figure 1. Lentivirus was produced and the viral titres were determined, as previously described [17]. The control vectors; LV-CMV-GFP (n=3) into the striatum (3 sites with 2 μl virus/site; A/P +0.6, M/L -2, D/V -5 and -4 (1μl/depth); A/P +0.6, M/L -3.2, D/V -5 and -4 (1μl/depth); A/P +1.2, M/L -2.5, D/V -5 and -4 (1μl/depth); all measured from the bregma and dural surface, with the tooth bar set to 0). Other animals were injected with a low dose of LV-EF1α-smiRNA1550 (n=6) or LV-EF1α-GFP (n=4) into the SNpr (1 site with 1 μl virus; A/P -5.3, M/L -2, D/V -7.6; all measured from the bregma and dural surface, with the tooth bar set to -2.3). Some were injected with a high dose of LV-EF1α-smiRNA1550 (n=6) or LV-EF1α-smiRNAαGFP (n=4) into the SNpr (2 sites with 1.5 μl virus/site; A/P -5.2, M/L -2.4, D/V -7).

Surgical procedures

A total of 54 adult female Sprague-Dawley rats were included in this study. The animals were housed in groups of 2-5 per cage under a 12 hour light-dark cycle with ad libitum access to food and water. All procedures were approved and performed according to the guidelines of the ethical committee for use of laboratory animals at Lund University. Animals were anesthetized using 6.2 ml/kg of a fentanyl-citrate (Fentanyl, B. Braun Melsungen AG, Melsungen, Germany, 50 μg/ml) and medetomidine hydrochloride (Domitor, Orion Pharma, Espoo, Finland, 1 mg/ml) mixture (20:1) injected ip. After all surgeries 0.9 ml/kg Atipamezol hydrochloride (Antisedan, Orion Pharma, 5mg/ml) in sterile water (1:15) and 1.3 ml/kg buprenorphine hydrochloride (Temgesic, Shering-Plough Europe, Heist-Op-Den-Berg, Belgium, 0.3 mg/ml) in sterile saline (1:9) were administered sc. A subgroup of animals (n=13) was used as intact controls. Remaining animals (n=41) were unilaterally lesioned using 6-hydroxydopamine (6-OHDA). Lesioned animals received an injection of 14 μg 6-OHDA (Sigma-Aldrich, St. Louis, MO) diluted to 3.5 μg/μl in a 0.02% ascorbic acid/saline solution, into the medial forebrain bundle (A/P -4.4, M/L -1.2, D/V -7.8; measured from the bregma and dural surface, with the tooth bar set to -2.4) using a 10 ml Hamilton syringe (Hamilton, Bonaduz, Switzerland). 3 weeks after the lesion, the animals were randomized into different groups and a subgroup of animals (n=28) were re-anesthetized and injected with virus using a 5 ml Hamilton syringe fitted with a glass capillary. Remaining animals (n=13) were used as lesion only controls. Animals were injected with LV-CMV-smiRNA1550 (n=5) or LV-CMV-GFP (n=3) into the striatum (3 sites with 2 μl virus/site: A/P +0.6, M/L -2, D/V -5 and -4 (1μl/depth); A/P +0.6, M/L -3.2, D/V -5 and -4 (1μl/depth); A/P +1.2, M/L -2.5, D/V -5 and -4 (1μl/depth); all measured from the bregma and dural surface, with the tooth bar set to 0). Other animals were injected with a low dose of LV-EF1α-smiRNA1550 (n=6) or LV-EF1α-GFP (n=4) into the SNpr (1 site with 1 μl virus; A/P -5.3, M/L -2, D/V -7.6; all measured from the bregma and dural surface, with the tooth bar set to -2.3). Some were injected with a high dose of LV-EF1α-smiRNA1550 (n=6) or LV-EF1α-smiRNAαGFP (n=4) into the SNpr (2 sites with 1.5 μl virus/site; A/P -5.2, M/L -2.4, D/V -7).

Figure 1. Schematic maps of the vector constructs.

A map of the constructs containing smiRNA1550 or smiRNAαGFP is shown in (A).

A map of the constructs containing GFP is shown in (B).

A CMV promoter was used in the smiRNA and GFP constructs in the striatal injections while an EF1α promoter was used in the smiRNA and GFP constructs in the striatal injections.
D/V -8; A/P -5.6, M/L -2.2, D/V-8; all measured from the bregma and dural surface, with the tooth bar set to -2.4). The animals belonging to the intact and lesion only groups were also anesthetized, an incision was made on the head and the wound was closed in order to make them indistinguishable from the virus-injected animals in the subsequent behaviour tests.

**Behavioural tests**
All behaviour tests and scoring of results were performed by an observer blind to the treatment given to the animal.

**Drug-induced rotations**
Drug induced rotations were assessed essentially as described by Ungerstedt and Arbuthnott [18] in automated rotometer bowls (Accuscan Instrument Inc, Columbus, Ohio). Rotations were monitored for 90 min following ip injection of D-amphetamine sulphate (2.5 mg/kg, Apoteksbolaget, Sweden) or for 40 min following sc injection of apomorphine-HCl (0.2 mg/kg, Sigma-Aldrich). Amphetamine rotations were used to assess the 6-OHDA lesion before viral injection. All animals included in the study achieved >4.3 turns/min after injection of D-amphetamine. The scores shown from the apomorphine-HCl experiments are expressed as counter-clockwise 360° turns/min.

**Corridor test**
The corridor test was performed essentially as described by Dowd et al [19]. Briefly, food restricted rats was first placed in an empty corridor (150*7*32 cm), to reduce exploratory behaviour, and then in a test corridor (150*7*32 cm) with 10 adjacent pairs of plastic lids. The animals were habituated in the 2 corridors for 5 min the first day. Some sugar pellets (Test Diet, Richmond, VA) were sprinkled in on the empty side and in some of the lids on the test side. On test days, all lids were filled with sugar pellets and the number of retrievals from the right and left side was counted. A retrieval was counted for each time the rat poked its head into a lid, regardless if any sugar pellets were eaten or not. Repeated retrievals from the same lid were not counted unless another lid was visited in between. Each rat was kept in the test corridor until 20 retrievals were achieved or 5 min had elapsed. All rats were tested for 4 consecutive days. The scores shown is the percentage of contralateral retrievals. Days when the animal did not achieve 20 retrievals were excluded.

**Spontaneous rotations**
Spontaneous rotations were assessed in automated rotometer bowls for 40 min. The scores shown from the experiments are expressed as clockwise 360° turns/min. Time periods when the rat was not moving was excluded.

**Western blot**
Animals were sacrificed using 1.5 ml sodium pentobarbital (Apoteket, Lund, Sweden, 60 mg/ml). The brains were briefly put in ice-cold saline and then coronally sectioned into three 1 mm and one 2 mm (most posterior part) sections to include the whole striatum or 1 mm of striatum and 2 mm of SNpr. The individual striatal and SNpr pieces were then dissected and placed in individual tubes. 3 ml/g (minimum 100μl) of RIPA buffer with protease inhibitor (Roche, Basel, Switzerland) was added to each sample and the samples were homogenized by sonication. The samples were left on ice for 30 min and were then centrifuged at 10,000xg for 10 min at 4°C to remove debris.

The protein concentration was determined using the Bio-Rad DC Protein assay kit (BioRad, Hercules, CA) according to the manufacturer's protocol. 5 μg of protein was loaded on the gel and Western blot was performed essentially as previously described [9]. Antibodies used: mouse anti-GAD67 (1:3000, sc-58531, Santa Cruz, Santa Cruz, CA), mouse anti-β-actin HRP (1:50000, MAB318, Millipore, Billerica, MA) and goat anti-mouse HRP (1:5000, sc-2005, Santa Cruz). The staining was detected by ECL prime (GE Healthcare, Waukesha, WI) and photographed using the Versadoc MP 4000 or ChemiDoc MP system (BioRad). The images were analyzed using Image lab (BioRad). The values were normalized first to actin (striatum) or the total amount of protein loaded (SNpr) and secondly to the untreated left side.

**Statistical analysis**
Differences between groups were assessed using analysis of variance (ANOVA) followed by the Tukey's multiple comparison test for group comparisons. Significance was accepted at a 95% probability level.

**Results**
**Injection of smiRNA1550 into rat striatum**
The ability of smiRNA1550 to alleviate motor symptoms was evaluated using 6-OHDA lesioned rats and LV. Lesioned rats were injected with LV-CMV-smiRNA1550 or LV-CMV-GFP at 3 sites (2 depths/site) in the striatum. There was no beneficial effect on behaviour following injection of LV-CMV-smiRNA1550 (data not shown). Analysis of the GAD67 protein level by Western blot showed an up-regulation of GAD67 protein level to 163±22% of the intact untreated side on the lesioned side of the “lesion only” control animals (Figure 2). By contrast, a maximal down-regulation to 45-108 % of the intact untreated side could be seen after injection of LV-CMV-smiRNA1550 into the lesioned side. These results show that smiRNA1550 has effect on the GAD67 protein level after injection into lesioned animals. The effect of smiRNA1550 was however limited to areas close to the injection site, targeting only a fraction of the total neurons in the striatum (Figure 2). We therefore hypothesised that we targeted a too small portion of the affected neurons to achieve any significant behavioural effect and the therapy could potentially be more beneficial in a smaller nucleus where a larger portion of the total cells could be targeted.
Injection of smiRNA1550 into rat substantia nigra pars reticulata

The smiRNA was further evaluated in the SNpr of 6-OHDA lesioned rats. We changed the promoter from CMV to EF1α since previous studies have shown that CMV is mainly expressed in glial cells in the midbrain [20]. Two experiments were performed: a low dose of LV-EF1α-smiRNA1550 or LV-EF1α-GFP was used in the first experiment while a higher dose of LV-EF1α-smiRNA1550 or LV-EF1α-smiRNAαGFP was used in the second experiment.

The effect of the gene therapy was evaluated using several behaviour tests: the corridor test [19], spontaneous rotations and apomorphine-induced rotations (Figure 3). The control groups, intact animals and lesion only animals, were similar and not significantly different in the two experiments and thus the results from these groups were combined to form one intact group and one lesion only group. Comparison between the intact control animals and lesion only animals showed that the 6-OHDA lesion induced a significant sensory motor neglect and rotational behaviour (Figure 3).

There was no significant beneficial effect in the corridor test (Figure 3A), although a trend towards increased left paw retrievals could be seen in the smiRNA1550 groups.
when compared to their respective control groups. No beneficial effect was seen in spontaneous rotations when the smiRNA1550 groups were compared to their respective control groups (Figure 3B). It is however worth noting that the smiRNA1550 low dose group was not significantly different from the intact group (0.466±0.166 vs -0.043±0.056 CW turns/min, p>0.05) and significantly different from the lesion only group (0.466±0.166 vs 1.98±0.169 CW turns/min, p<0.05). A beneficial effect could be seen in apomorphine-induced rotations (Figure 3C) where the smiRNA1550 low dose group was statistically different to the GFP low dose control group (1.770±1.144 vs 10.223±2.634 turns/min p<0.0001). Additionally, neither of the smiRNA1550 groups was statistically different from the intact control group (1.770±1.144 (low dose) and 2.191±1.079 (high dose) vs -0.038±0.018 CCW turns/min, p>0.05). These results indicate that expression of smiRNA1550 has beneficial, i.e., normalising, effect on motor behaviour in 6-OHDA lesioned rats.

The GAD67 protein levels in SN were analysed by Western blot (Figure 4). Both the SNpr and the substantia nigra pars compacta (SNpc) were included in the dissected piece due technical limitations and included in the Western blot samples. There was no significant difference after lesion or following injection of either of the smiRNA1550 doses, GFP or smRNAaGFP (lesion only: 111±18%; smiRNA1550 low: 98±18%; GFP: 77% (average of 2 animals); smiRNA1550 high: 78±12%; smRNAaGFP: 86±20% of untreated intact side) when compared to intact untreated animals (100±10%). We chose to normalise the values to the amount of protein loaded instead of actin since we frequently noted an increased actin level in the samples taken from the lesioned side. The 6-OHDA lesion was validated by Western blot, using antibodies directed against tyrosine hydroxylase (TH). All animals included in this study were well lesioned (Figure 4).

Discussion

In this study we have used a smiRNA based on miR30 to knock-down the endogenous GAD67 level. Furthermore, we have evaluated its effects on behaviour in the 6-OHDA rat model of PD after injection into the striatum or the SNpr. GAD67 has been shown to play a pivotal role in the synthesis of GABA and amount of vesicular GABA [21,22]. A recent study by Lau et al., [22] has shown that GAD67 expression is upregulated by neuronal activity and down-regulated by neuronal inactivity. These changes were strongly correlated to a corresponding increase or decrease in the synthesis and vesicular filling of GABA, indicating that GAD67 regulate GABA levels in an activity-dependent manner. Since smiRNA1550 has been shown to regulate the level of endogenous GAD67 protein [9], it is possible that the GABA output from a smiRNA-expressing nucleus is modified. The use of miR30 based silencing constructs has several advantages over similar constructs using shRNA. Several studies have noted an increased cytotoxicity when expressing high levels of shRNA [12,13,23]. This could potentially be detrimental for therapeutic use of this type of RNAi, especially when using viral vectors in vivo where it may not be possible to control the multiplicity of infection. This has indeed been noted in studies using shRNA for example in the brain [12,13] and in the liver [23]. The cause of this toxicity has been suggested to involve saturation of the miRNA system and disruption in the biogenesis of endogenous miRNAs. No such toxicity has been noted when using a smiRNA, even when dosed to silence as efficiently as shRNA [12,13]. The design of the gene therapy vector is also more flexible when using a smiRNA.

Transcription of shRNA using a pol II promoter can occur but the spacing of the hairpin to the transcription start site has to be carefully optimised to ensure production of functional shRNA [24]. A pol III promoter is therefore generally used for shRNA since this type of promoter provides a strict control of the transcription initiation and termination sites. By contrast, smiRNA has no such requirements and can therefore be readily transcribed by both pol II and pol III promoters [11,14]. This enables easy use of cell specific or regulatable promoters that further enhance the specificity and safety of the gene therapy. A reporter, such as GFP or dsRed, can also be easily included in the smiRNA vector to allow tracking of cells containing the smiRNA [11,17].

We started by evaluating the effect of smiRNA1550 in the striatum of 6-OHDA lesioned rats. The lowest GAD67 protein levels obtained after injection of smiRNA1550 into the lesioned side ranged from 45-108% of the intact untreated side, showing an efficient down-regulation of the lesion-induced upregulation of GAD67 seen after injection of 6-OHDA. This level of down-regulation is similar to the levels found around the injection site in the striatum on the lesioned side in our previous study [9]. The effect of smiRNA1550 on GAD67 protein levels was however limited to an area close to the injection site in this study and this partial striatal down-regulation was
not sufficient to induce any behavioural benefits. We therefore hypothesised that smiRNA1550 could be more beneficial in a smaller nucleus, such as SNpr.

Previous studies have used deep brain stimulation (DBS), lesions, glutamate receptor antagonists or GABAA receptor agonists to evaluate the therapeutic effect of SNpr manipulation in rodent and primate PD models and parkinsonian patients. The main beneficial effect found in these studies was on axial symptoms of PD [25-27], such as posture and gait, while the effect on arm and leg akinesia and bradykinesia has been more varied with some studies showing a positive effect and some showing no effect [27-29]. Modification of SNpr is not as efficient as modification of STN in treatment of parkinsonian symptoms [26]. Recent studies on parkinsonian patients have however reported that combined DBS of STN and SNpr has some additional beneficial effects on gait when compared to DBS of STN alone [30,31]. To our knowledge, this is the first study using gene therapy in an attempt to modify SNpr activity in a parkinsonian model.

We could not detect any beneficial effect on sensorimotor neglect in the group receiving smiRNA1550 when assessed by the corridor test. This is in line with previous studies that have shown no effect on sensorimotor neglect following SNpr manipulation in PD animal models [25,27]. As reported in previous studies, the 6-OHDA lesion caused a small spontaneous ipsilateral rotational bias [18]. Injection of a GABA agonist or a glutamate antagonist into the SNpr of 6-OHDA lesioned rats has previously been shown to induce spontaneous contralateral rotations [32,33]. There was no statistically significant beneficial effect on spontaneous rotation following injection of smiRNA1550 into the SNpr in this study. There was however a trend towards a reduced rotational behaviour the smiRNA1550 low dose group. Injection of apomorphine induced a strong contralateral rotation in 6-OHDA lesioned rats in this study, which is in line with previous studies [34]. In contrast to the spontaneous rotations, the apomorphine-induced rotations were significantly reduced in animals expressing a low dose of smiRNA1550. Rats with both a 6-OHDA lesion and a lesion of the SNpr has previously been shown to have an altered rotational behaviour when compared to 6-OHDA lesioned rats after injection of apomorphine [34,35]. In these previous studies, the additional lesion in SNpr was shown to reduce the contralateral rotations induced by the 6-OHDA after injection of apomorphine. Furthermore, increased doses of apomorphine or repeated injections over several days further attenuated the rotations and at high doses or several repeated doses even reversed the direction of the rotations. It is possible that smiRNA1550 has a similar, but milder, effect as a GABA agonist, glutamate antagonist or SNpr lesion and is therefore able to reduce some types of rotational behaviour. In the high dose experiment there was no significant difference between the groups. The main difference in the data consisted of a lower rotational response in the control group. This could be due to toxicity of the vector it self, a phenomenon that has been described previously (see e.g., [12]). Some studies have reported adverse effects following manipulations of SNpr. Acute tonic-clonic seizures has been reported after kainic acid lesion of the mid-SNpr in naive and 6-OHDA lesioned rats [25] and acute depression or hypomania has been reported in patients following DBS in SNpr [36,37]. No severe adverse effects, such as seizures, were noted following injection of LV-EF 1a-smiRNA1550 into the SNpr in this study, but this needs to be further evaluated since no tests assessing non-motor symptoms were performed.

We chose to normalise the GAD67 protein level obtained from the Western blot to the amount of protein loaded instead of actin in the SN samples, since we frequently noted an increased actin level on the lesioned side compared to the intact side. This increased actin level may be caused by astrogliosis and/or infiltrating microglia [38,39]. These cell types have both been shown to increase in SNpc following injection of 6-OHDA into the medial forebrain bundle (MFB). Since the SNpr is very small to dissect, both the reticulata and the compacta part of the SN were included in the dissections and it is therefore possible that these infiltrating cells could influence the result. Previous studies have shown an increase of GAD67 in SNpr of 6-OHDA lesioned rats [10]. No effect on the GAD67 protein level could be seen in any of the groups in this study. It is however possible is that the effect of the therapy is masked by the extra tissue included in the dissec- tion. The effect of smiRNA1550 on the GAD67 protein level in SNpr therefore needs to be further evaluated.

**Conclusion**

The present report show that injection of smiRNA directed against GAD67 can have beneficial effects on behaviour in rats with unilateral dopamine-depletions. This validates further investigations in models of Parkinson’s disease as well as in other disorders where GABA is known to play and important role.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

| Authors’ contributions                               | EEW | LQ | CL |
|-------------------------------------------------------|-----|----|----|
| Research concept and design                           | ✓   |    |    |
| Collection and/or assembly of data                    | ✓   |    |    |
| Data analysis and interpretation                      | ✓   | ✓  | ✓  |
| Writing the article                                   | ✓   |    | ✓  |
| Critical revision of the article                      | ✓   | ✓  |    |
| Final approval of article                             | ✓   | ✓  |    |
| Statistical analysis                                  | --  | ✓  | -- |

**Acknowledgement and funding**

We would like to thank Christina Isaksson, Michael Sparrenius, Anneli Josefsson and Ulla Jarl for technical assistance. Thanks also to Ingrid Van Marion and master student Clara Gomis
Coloma for assistance with vector construction. This work was supported by the Swedish Research Council (# 2010-4496 and 2007-8626) and the Swedish Parkinson Foundation.

References

1. Mitchell UJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA and Crossman AR. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 1989; 32:213-26. | Article | PubMed

2. Galvan A and Wichmann T. GABAergic circuits in the basal ganglia and movement disorders. Prog Brain Res. 2007; 160:287-312. | Article | PubMed

3. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML and During MJ. Subthalamic GAD gene therapy in a Parkinson’s disease rat model. Science. 2002; 298:425-9. | Article | PubMed

4. Lee B, Lee H, Nam YR, Oh JH, Cho YH and Chang JW. Enhanced motor function and cortical metabolism in rats with subthalamic glutamic acid decarboxylase gene therapy in the Parkinsonian state. Neurosci Lett. 2007; 410:169-75. | Article | PubMed

5. Emborg ME, Carbon M, Holden JE, During MJ, Ma Y, Tang C, Moirano J, Fitzsimons H, Roitberg BZ, Tuccar E, Roberts A, Kaplitt MG and Eidelberg D. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab. 2007; 27:501-9. | Article | PubMed

6. Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, During MJ and Eidelberg D. The effect of metabolic brain networks after subthalamic gene therapy for Parkinson’s disease. Proc Natl Acad Sci U S A. 2007; 104:19559-64. | Article | PubMed Abstract | PubMed Full Text

7. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D and During MJ. Safety and tolerability of gene therapy with an adenovirus-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet. 2007; 369:2097-105. | Article | PubMed

8. LeWitt PA, Rezai AR, Leehey MA, Ojemann GA, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS and Tatler SB et al. AAV-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery-controlled, randomised trial. Lancet Neurol. 2011; 10:309-19. | Article | PubMed

9. Horvath L, van Marion I, Tai K, Nielsen TT and Lundberg C. Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson’s disease. J Gene Med. 2011; 13:188-97. | Article | PubMed

10. Carta AR, Tabrizi MA, Baraldi PG, Pinna A, Pala P and Morelli M. Blockade of A2A receptors plus I-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from I-DOPA alone in the rat globus pallidus and substantia nigra reticulata. Exp Neurol. 2003; 184:679-87. | Article | PubMed

11. Stegemeyer F, Hu G, Rickles RJ, Hannon GJ and Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A. 2005; 102:13212-7. | Article | PubMed Abstract | PubMed Full Text

12. McBride JL, Boudreau RL, Harper SQ, Staber PD, Montey AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ and Davidson BL. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008; 105:35868-73. | Article | PubMed Abstract | PubMed Full Text

13. Boudreau RL, Martins I and Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther. 2009; 17:169-75. | Article | PubMed Abstract | PubMed Full Text

14. Li L, Lin X, Khvorova A, Fesik SW and Shen Y. Defining the optimal parameters for hairpin-based knockdown constructs. RNA. 2007; 13:1765-74. | Article | PubMed Abstract | PubMed Full Text

15. Erdinger MG, Tillakaratne NJ, Feldblum S, Patel N and Tobin AJ. Two genes encode distinct glutamate decarboxylases. Neuron. 1991; 7:91-100. | Article | PubMed

16. Jakobsson J, Ericson C, Jansson M, Bjork E and Lundberg C. Targeted transgene expression in rat brain using lentiviral vectors. J Neurosci Res. 2003; 73:876-85. | Article | PubMed

17. Nielsen TT, Marion I, Hasholt L and Lundberg C. Neuron-specific RNA interference using lentiviral vectors. J Gene Med. 2009; 11:559-69. | Article | PubMed

18. UngersdotT U and Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970; 24:485-93. | Article | PubMed

19. Dowed E, Monville C, Torres EM and Dunnett SB. The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res Bull. 2005; 68:24-30. | Article | PubMed

20. Rosenblad C, Gronborg M, Hansen C, Blom N, Meyer M, Johansen J, Dago L, Krik D, Patel UA, Lundberg C, Trono D, Bjorklund A and Johansen TE. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artertin. Mol Cell Neurosci. 2000; 15:199-214. | Article | PubMed

21. Asada H, Kawamura Y, Maruyama K, Kume H, Ding RG, Kanbara N, Kuzume H, Sanbo M, Yagi T and Obata K. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci U S A. 1997; 94:6436-9. | Article | PubMed Abstract | PubMed Full Text

22. Lau CG and Murthy VN. Activity-dependent regulation of inhibition via GAD67. J Neurosci. 2012; 32:8521-31. | Article | PubMed Abstract | PubMed Full Text

23. Grimm D, Streezt KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marlon P, Salazar F and Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006; 441:537-41. | Article | PubMed

24. Xia H, Mao Q, Paulson HL and Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol. 2002; 20:1006-10. | Article | PubMed

25. Henderson JM and Watson SH. Convulsive and postural effects of lesioning the mid-substantia nigra pars reticulata in naive and 6-hydroxydopamine lesioned rats. Brain Res. 2003; 60:179-85 S. | Article | PubMed

26. Chastan N, Westby GW, Yelnik J, Bardinet E, Do MC, Agid Y and Welter ML. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson’s disease. Brain. 2009; 132:172-84. | Article | PubMed

27. Henderson JM, Stanic D, Tomas D, Patch J, Horne MK, Bourke D and Finkelstein DI. Postural changes after lesions of the substantia nigra in human. Behav Brain Res. 2005; 160:267-76. | Article | PubMed

28. Wichmann T, Kliem MA and DeLong MR. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian monkeys. Behav Brain Res. 2005; 158:559-69. | Article | PubMed

29. Sutton AC, Yu W, Calos ME, Smith AB, Ramirez-Zamora A, Molho ES, Pliitis JG, Brotchie JM and Shin DS. Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat. J Neurophysiol. 2013; 109:363-74. | Article | PubMed

30. Weiss D, Breit S, Wachter T, Plewnia C, Gharabaghi A and Kruger R. Combined stimulation of the substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait disturbance in Parkinson’s disease. J Neurosci. 2011; 258:1183-5. | Article | PubMed

31. Weiss D, Walach M, Meisner C, Fritz M, Scholten M, Breit S, Plewnia C,
Bender B, Gharabaghi A, Wachter T and Kruger R. Nigral stimulation for resistant axial motor impairment in Parkinson's disease? A randomized controlled trial. *Brain*. 2013; 136:2098-108. | Article | PubMed Abstract | PubMed Full Text

32. Kozlowski MR and Marshall JF. Rotation induced by intranigral injections of GABA agonists and antagonists: zone-specific effects. *Pharmacol Biochem Behav*. 1980; 13:561-7. | Article | PubMed

33. St-Pierre JA and Bedard PJ. Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model. *Brain Res*. 1994; 660:255-60. | Article | PubMed

34. Dewar D, Jenner P and Marsden CD. Lesions of the globus pallidus, entopeduncular nucleus and substantia nigra alter dopamine mediated circling behaviour. *Exp Brain Res*. 1983; 52:281-92. | Article | PubMed

35. Herrera-Marschitz M and Ungerstedt U. Evidence that striatal efferents relate to different dopamine receptors. *Brain Res*. 1984; 323:269-78. | Article | PubMed

36. Bejjani BP, Damier P, Arnulf I, Thivard L, Bonnet AM, Dormont D, Cornu P, Pidoux B, Samson Y and Agid Y. Transient acute depression induced by high-frequency deep-brain stimulation. *N Engl J Med*. 1999; 340:1476-80. | Article | PubMed

37. Ulla M, Thobois S, Llorca PM, Derost P, Lemaire JJ, Chereau-Boudet I, de Chazeron I, Schmitt A, Broussolle E and Durif F. Contact dependent reproducible hypomania induced by deep brain stimulation in Parkinson's disease: clinical, anatomical and functional imaging study. *J Neurol Neurosurg Psychiatry*. 2011; 82:607-14. | Article | PubMed

38. Stromberg I, Bjorklund H, Dahl D, Jonsson G, Sundstrom E and Olson L. Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. *Brain Res Bull*. 1986; 17:225-36. | PubMed

39. Marinova-Mutafchieva L, Sadeghian M, Broom L, Davis JB, Medhurst AD and Dexter DT. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson’s disease. *J Neurochem*. 2009; 110:966-75. | Article | PubMed

Citation:
Wettergren EE, Quintino L and Lundberg C. Gene therapy using synthetic microRNA directed against GAD67 has beneficial effect on motor behaviour in 6-OHDA lesioned rats. *J Gene Ther Aspects*. 2014; 1:1.
http://dx.doi.org/10.7243/2057-164X-1-1